Literature DB >> 19154511

Early onset of fibrosis within the arterial media in a rat model of type 2 diabetes mellitus with erectile dysfunction.

Istvan Kovanecz1, Gaby Nolazco, Monica G Ferrini, Jorge E Toblli, Sanaz Heydarkhan, Dolores Vernet, Jacob Rajfer, Nestor F Gonzalez-Cadavid.   

Abstract

OBJECTIVES: To determine, in the obese Zucker fa/fa rat (OZR), whether the loss in smooth muscle cells (SMCs) as well as the increase in fibrosis that occurs within the corpora cavernosa accompanying corporal veno-occlusive dysfunction (CVOD), also occurs within the media of the arterial tree.
MATERIALS AND METHODS: The penis and aorta from both 7-month-old male diabetic OZR (5 months of diabetes) and aged-matched nondiabetic lean Zucker rats (LZR) rats were harvested (eight per group). The penis and aorta were subjected to histo- or immnohistochemistry, followed by quantitative image analysis (QIA) to determine the contents of SMC, collagen and the pro-fibrotic transforming growth factor (TGF)beta1. The turnover of SMCs was assessed by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labelling (TUNEL) and proliferating cell nuclear antigen (PCNA) assays. Quantitative Western blots determined calponin (SMC marker) and PCNA, and hydroxyproline was used for collagen. In vitro relaxation of corporal strips was measured.
RESULTS: In vitro relaxation of corporal tissue from OZR was considerably less than in the LZR. In the media of the penile dorsal artery (PDA) of OZR, there was a considerable reduction in the SMC content and the SMC/collagen ratio, as well as an increase in apoptosis, but there were no changes in PCNA or TGFbeta1 expression, or in the intima-media/lumen ratio. In the aorta of the OZR, in contrast to the PDA, there was a reduction in PCNA as well as a more pronounced decrease in the SMC/collagen ratio, mainly from an increase in collagen, but there were no changes in TGFbeta1 or the wall/lumen morphometry. In the OZR, Western blots of aortic tissue confirmed the decrease in PCNA and a reduction in the SMC marker calponin.
CONCLUSIONS: These data show that 5 months after the onset of hyperglycaemia in the OZR, the rats develop both abnormal corporal SMC relaxation and a generalized fibrosis of the arterial media of both the large and small diameter vessels. It is possible that this pan-fibrosis of the media of the arterial system might contribute to the diabetes-related ED that occurs during this period in this rat model.

Entities:  

Mesh:

Year:  2009        PMID: 19154511     DOI: 10.1111/j.1464-410X.2008.08251.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  19 in total

1.  Constitutive NOS uncoupling and NADPH oxidase upregulation in the penis of type 2 diabetic men with erectile dysfunction.

Authors:  B Musicki; A L Burnett
Journal:  Andrology       Date:  2017-01-11       Impact factor: 3.842

2.  Dyslipidemia Is a Major Factor in Stem Cell Damage Induced by Uncontrolled Long-Term Type 2 Diabetes and Obesity in the Rat, as Suggested by the Effects on Stem Cell Culture.

Authors:  Maryam Masouminia; Robert Gelfand; Istvan Kovanecz; Dolores Vernet; James Tsao; Ruben Salas; Kenny Castro; Leila Loni; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  J Sex Med       Date:  2018-12       Impact factor: 3.802

3.  Long-term phosphodiesterase 5 inhibitor administration reduces inflammatory markers and heat-shock proteins in cavernous tissue of Zucker diabetic fatty rat (ZDF/fa/fa).

Authors:  J E Toblli; G Cao; M Angerosa; M Rivero
Journal:  Int J Impot Res       Date:  2015-07-23       Impact factor: 2.896

4.  Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus.

Authors:  Jorge E Toblli; Monica G Ferrini; Gabriel Cao; Dolores Vernet; Margarita Angerosa; Nestor F Gonzalez-Cadavid
Journal:  Nephrol Dial Transplant       Date:  2009-03-17       Impact factor: 5.992

Review 5.  Basic Science Evidence for the Link Between Erectile Dysfunction and Cardiometabolic Dysfunction.

Authors:  Biljana Musicki; Anthony J Bella; Trinity J Bivalacqua; Kelvin P Davies; Michael E DiSanto; Nestor F Gonzalez-Cadavid; Johanna L Hannan; Noel N Kim; Carol A Podlasek; Christopher J Wingard; Arthur L Burnett
Journal:  J Sex Med       Date:  2015-12-08       Impact factor: 3.802

6.  Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension.

Authors:  C S Oxlund; C Cangemi; J E Henriksen; I A Jacobsen; J Gram; K Schousboe; L Tarnow; W S Argraves; L M Rasmussen
Journal:  J Hum Hypertens       Date:  2014-04-17       Impact factor: 3.012

7.  Implanted Muscle-Derived Stem Cells Ameliorate Erectile Dysfunction in a Rat Model of Type 2 Diabetes, but Their Repair Capacity Is Impaired by Their Prior Exposure to the Diabetic Milieu.

Authors:  Istvan Kovanecz; Dolores Vernet; Maryam Masouminia; Robert Gelfand; Leila Loni; James Aboagye; James Tsao; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  J Sex Med       Date:  2016-05       Impact factor: 3.802

8.  Effects of sildenafil and/or muscle derived stem cells on myocardial infarction.

Authors:  Judy Sc Wang; Istvan Kovanecz; Dolores Vernet; Gaby Nolazco; George E Kopchok; Sheryl L Chow; Rodney A White; Nestor F Gonzalez-Cadavid
Journal:  J Transl Med       Date:  2012-08-07       Impact factor: 5.531

9.  Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction.

Authors:  Murat Savas; Ercan Yeni; Ayhan Verit; Mehmet Gulum; Nurten Aksoy; Halil Ciftci; Hakim Celik; Adem Altunkol; Halil Oncel
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

10.  Evaluation of the effect of different doses of low energy shock wave therapy on the erectile function of streptozotocin (STZ)-induced diabetic rats.

Authors:  Jing Liu; Feng Zhou; Guang-Yong Li; Lin Wang; Hui-Xi Li; Guang-Yi Bai; Rui-Li Guan; Yong-De Xu; Ze-Zhu Gao; Wen-Jie Tian; Zhong-Cheng Xin
Journal:  Int J Mol Sci       Date:  2013-05-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.